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Abstract
Tetrabromobisphenol A (TBBPA) is a ubiquitous brominated flame retardant, showing 
widespread environment and human exposures. A variable domain of the heavy chain antibody 
(VHH), naturally occurring in camelids, approaches the lower size limit of functional antigen-
binding entities. Ease of genetic manipulation makes such VHHs a superior choice to use as an 
immunoreagent. In this study, a highly selective anti-TBBPA VHH T3-15 fused with alkaline 
phosphatase (AP) from E. coli was expressed, showing both an integrated TBBPA-binding 
capacity and enzymatic activity. A one-step immunoassay based on the fusion protein T3-15-AP 
was developed for TBBPA in 5% dimethyl sulfoxide (DMSO)/phosphate buffered saline (PBS, 
pH 7.4), with a half-maximum signal inhibition concentration (IC50) of 0.20 ng mL−1. Compared 
to the parental VHH T3-15, T3-15-AP was able to bind to a wider variety of coating antigens and 
the assay sensitivity was slightly improved. Cross-reactivity of T3-15-AP with a set of important 
brominated analogs was negligible (<0.1%). Although T3-15-AP was susceptible to extreme heat 
(90 °C), much higher binding stability at ambient temperature was observed in the T3-15-AP 
based assay for at least 70 days. A simple pretreatment method of diluting urine samples with 
DMSO was developed for a one-step assay. The recoveries of TBBPA from urine samples by this 
one-step assay ranged from 96.7–109.9% and correlated well with an HPLC-MS/MS method. It is 
expected that the dimerized fusion protein, VHH-AP, will show promising applications in human 
exposure and environmental monitoring.
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INTRODUCTION
Enzyme linked immunosorbent assay (ELISA) is routinely used for small molecules such as 
pesticides, drugs, and hormones in environmental and biomedical analysis due to its 
sensitivity, simplicity and high-throughput. Numerous ELISAs for small molecules are 
performed in a two-step competitive protocol which normally requires the addition of a 
primary (recognition) antibody followed by a secondary antibody chemically conjugated to 
an enzyme such as horseradish peroxidase (HRP) or alkaline phosphatase (AP). 
Alternatively, a one-step protocol that avoids the use of secondary antibodies has been 
developed with either the analyte or the recognition antibody chemically conjugated with 
enzymes or other reporters 1. The chemical conjugation methods may cause random cross-
linking of molecules 2, leading to the loss of the enzyme activity or the antibody binding 
avidity to some extent. Also, the molecular ratio of such conjugate is hard to control and 
costly reagents are required. An attractive alternative method is genetically constructing a 
fusion protein of enzyme and antibody3, 4, thus eliminating the use of chemically produced 
antibody–enzyme conjugates when performing ELISAs. Advances in recombinant DNA 
technology enabled the production of single-chain variable fragments (scFv) and AP fusion 
proteins which have been demonstrated to preserved the binding and enzyme activity3. 
However, the poor affinity, solubility and stability of scFv may influence the interaction of 
fusion protein with target antigens 2, 5.
As an alternative to scFv, the variable domain of heavy chain antibody (VHH), a fragment 
derived from the camelid antibody devoid of light chain, is able to bind antigens comparable 
to conventional antibodies (polyclonal and monoclonal antibodies, pAbs 6, 7, 8 and mAbs 9). 
The VHH is smaller (around 15KD) than the scFv while showing greater thermal stability 
and solubility. Its concave-shaped paratopes make it robust 10 and able to recognize active 
sites normally inaccessible or cryptic for pAbs and mAbs 11. The ability of camelid VHHs to 
refold following heat or chemical denaturation is not observed for conventional antibodies 
or their recombinant fragments, i.e. scFv 12. VHHs can be genetically manipulated and 
easily cloned in bacteria 13, fungi 14 and even in plants 15 to pursue a variety of applications. 
Camelid VHHs genetically fused with green fluorescent proteins (GFP) proved to have both 
functional of VHH and GFP 16, serving as a tracer for antigens in live cells. The production 
of VHH-AP fusions specific for cholera toxin (CTX), ricin, staphylococcal enterotoxin B 
(SEB) 17 and ochratoxin A18 have also been described. These VHH-AP fusions not only 
provide an enhanced affinity but also function as a combined target recognition and signal 
transduction molecule. These VHH-based fusion proteins simplified assay protocols, 
showed good solubility and reproducibility, and therefore have been gaining increasing 
attention in numerous biotechnological applications 19, 20. To explore the possibility of 
expanding the scope of this technology to environmental monitoring, in this study we 
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developed a VHH-AP based one-step immunoassay for the small molecule pollutant 
tetrabromobisphenol A (TBBPA).
TBBPA has the largest worldwide market among all of the brominated flame retardants 
(BFRs) 21. It was widely used as a reactive flame retardant, covalently bound to printed 
circuit boards, epoxy and polycarbonate resins, and also as an additive flame retardant added 
to acrylonitrile–butadiene–styrene (ABS) resins or high impact polystyrene (HIPS) 21. The 
widespread usage of TBBPA has led to accumulation in abiotic and biotic matrices 22–24 and 
increased the concern regarding food safety and health in spite of its low toxicity 25. 
Although the exposure risk of TBBPA to the general population is low 26, there are risks 
associated with exposure to contaminated dust in occupational setting 27. Gas and liquid 
chromatography based techniques are the general methods in detecting TBBPA in various 
samples 28–30. As an alternative, immunoassays have been developed for TBBPA for 
environmental detection with high sensitivities 31–34. In an earlier work, we reported the 
selection of VHHs specific for TBBPA from an immunized alpaca VHH-derived library and 
the development of a VHH-based ELISA with a half-maximum signal inhibition 
concentration (IC50) of 0.4 ng mL−1 TBBPA 7.
VHH-AP fusion proteins have been used to develop quick immunoassays for large 
molecules 17, but it remains to be demonstrated if such constructs are suitable for small 
molecules. In this study, five anti-TBBPA VHH fusion with AP were expressed and used to 
develop a one-step ELISA for monitoring TBBPA in human urine. In addition, the binding 
ability and thermal stability were also measured and compared between the VHH-AP fusion 
proteins and the parental VHHs. This work presents VHH-AP fusion protein is a potential 
immunoreagent in environmental monitoring for small molecules.
EXPERIMENTAL SECTION
Safety
All the sharps were disposed into sharps disposal containers, according to campus policies 
of the University of California, Davis. TBBPA and its analogs were discarded as hazardous 
waste and the tubes containing urine samples were discarded as biological waste.
Materials and Methods
The synthesis of haptens T1–T6 (Figure S-1 in Supporting Information) and the selection of 
anti-TBBPA VHHs were described in previous studies 7, 32. The TBBPA standard was 
purchased from TCI Co. Ltd. (Tokyo, Japan). TBBPA derivatives and other BFR analogs 
were purchased from AccuStandard (New Haven, CT, USA). Plasmid pecan 45 encoding 
AP genes was a generous gift from Dr. Jinny L. Liu and Dr. Ellen R. Goldman from the 
Naval Research Laboratory, Washington D.C.. Isopropyl-β-D-thiogalactopyranoside 
(IPTG), p-nitrophenyl phosphate (pNPP), bovine serum albumin (BSA) and imidazole were 
purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO. USA). All restriction enzymes 
and T4 DNA ligase were bought from New England Biolabs, Inc. (Ipswich, MA. USA). 
HisPur Ni-NTA resin, B-PER, Halt protease inhibitor cocktail, and Nunc MaxiSorp flat-
bottom 96 well plates were purchased from Thermo Fisher Scientific Inc. (Rockford, IL, 
USA).
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Preparation of the Fusion Protein VHH-AP
According to the amino acid sequences of the complementarity determining regions (CDRs) 
(Figure S-2 in Supporting Information), five anti-TBBPA VHHs (T3-4, T3-9, T3-12, T3-15, 
and T3-16) were selected using coating antigen T3-BSA and encoded in the pComb 3X 
vector. VHH genes were amplified by PCR (Forward primer: 5′-CAT GCC ATG GTG GCC 
CAG CCG GCC CAT KTG CAT CTC GTG GAG TCN GGN GG. Reverse primer 1: 5′-
CAT GCC ATG ACT CGC GGC CCC CGA GGC CTC GTG GGG GTC TTC GCT GTG 
GTG CG; Reverse primer 2: 5′-CAT GCC ATG ACT CGC GGC CCC CGA GGC CTG 
GCC TTG TTT TGG TGT CTT GGG) and cloned into the AP-plasmid (pecan 45) using 
complementary Sfi I restriction sites. The VHH plasmid and VHH-AP plasmid were 
transformed to E. coli TOP 10F′ and BL21(DE3)pLysS, respectively, by heat shock. The 
proteins were expressed by 0.5 mM IPTG induction and purified with Ni-NTA resin by 
using 150 mM imidazole in PBS (0.01 mol L−1 phosphate, 0.137 mol L−1 NaCl, 3 mmol L−1 
KCl, pH 7.4) for elution. The size and purity of VHHs and VHH-APs were determined by 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE). The VHHs and 
fusion VHH-APs were collected and stored at 20 °C after dialysis with 0.01 M PBS.
One-step ELISA Performance
Haptens T1–T6 coupled to the carrier protein BSA were used as coating antigens. One-step 
competitive ELISAs were carried out as follows. A microtiter plate was coated overnight 
with 100 μL of coating antigen (1μg mL−1) in 0.05 mol L−1 carbonate-bicarbonate buffer 
(pH 9.6) at 4 °C. The plate was blocked with 3% skim milk in PBS (pH 7.4) at ambient 
temperature for 1 h. After washing with PBST (PBS containing 0.05% Tween-20), 50 μL 
per well of serial dilutions of TBBPA were added to the plate, followed by 50 μL of the 
VHH-APs, the concentrations of which have been determined by checkerboard titration. 
After incubation at ambient temperature for 1 h, the plate was washed and the AP activity 
was determined by addition of 150 μL of 1.0 mg mL−1 pNPP (1 M glycine buffer, 1 mM 
MgCl2 and 1 mM ZnCl2, pH 10.4). The reaction was stopped at 10 min by addition of 50 μL 
of 3 M NaOH solution, and the absorbance was read in a microtiter plate reader (Molecular 
Devices, Sunnyvale, CA, USA) at 405 nm. The IC50 value was obtained from a four-
parameter logistic equation generated by SigmaPlot 10.0. The indirect competitive VHH-
based ELISA was developed in our previous work 7. In this study, T3-15-AP was selected to 
optimize and develop a one-step immunoassay.
Optimization of ELISA
The effects of organic solvents and pH on ELISA performance (IC50 and maximal signal 
(A0)) were studied at ambient temperature. The TBBPA was separately dissolved in PBS 
containing different concentrations of dimethyl sulfoxide (DMSO) or methanol (MeOH) (0, 
5, 10, 20, 40, and 60%, v/v). The effects of buffer pH in a range of 4.0–11.0 on the assay 
were evaluated. Except the single variable, the rest of the assay conditions were the same as 
described above.
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The specificity of the T3-15-AP based assay was determined by its cross-reactivity (CR) 
with a group of structural analogs in a range of 0–2000 ng mL−1. The cross-reactivity was 
calculated with the equation as follows: CR (%) = [IC50(TBBPA)/IC50(tested compound)]
×100.
Stability of VHH-AP
For the thermal stability study, fusion protein T3-15-AP was incubated at 90 °C for 10, 20, 
30, 60, and 90 min, followed by cooling to ambient temperature. The capacity of T3-15-AP 
binding to the coating antigen T5-BSA was subsequently evaluated by ELISA. Meanwhile, 
the T3-15 was treated in the same way as above and the binding ability to T3-BSA was 
evaluated. With regard to long-term storage, both the T3-15 and T3-15-AP were stored at 
ambient temperature without any protective reagents and the binding activities were 
determined on day 1, 4, 8, 12, 20, 30, and 70.
Matrix Effects
The one-step immunoassay was applied to urine samples from volunteers for monitoring 
human exposure to TBBPA. Matrix effects were evaluated following a simple dilution 
protocol. In brief, blank urine samples were directly diluted with DMSO to form the final 
percentages of 10, 20, 40, and 60% of DMSO/urine (v/v) and a series concentration of 
TBBPA were spiked into each. After gently shaking for 10 min, the samples were 
centrifuged at 10,000 ×g for 10 min at ambient temperature and the supernatant was 
subjected to a one-step assay. The IC50 and A0 were compared with those of assays for 
TBBPA prepared in PBS containing different percentage of DMSO (10, 20, 40, and 60%) to 
evaluate the matrix effect.
Sample Analysis
Urine samples fortified with TBBPA (0.5, 1, 5, 20, 50, and 100 ng mL−1) were diluted with 
DMSO to reach a final percentage of 60% of DMSO/urine (v/v). After completely mixing, 
the diluted samples were centrifuged as above and the supernatants were subjected to the 
one-step assay using a calibration curve generated in PBS containing 60% DMSO.
For HPLC-MS/MS method, 10 μL of formic acid and 3 mL of ethyl acetate were added into 
1 mL of urine sample, followed by vortexing and ultrasonication for 20 min. The organic 
layer was collected after centrifugation at 3000 ×g for 20 min. The extraction steps were 
repeated 3 times. The extracts were vacuum dried and reconstituted with MeOH (1 mL) for 
use. The analysis by HPLC-MS/MS (Waters/Micromass, Manchester, UK) was carried out 
as described previously 7, except for that the running time was 12 min on the HPLC column.
RESULTS AND DISCUSSION
Production of VHH-AP Fusions
VHHs against TBBPA were biopanned from a T5-thyroglobulin immunized alpaca VHH-
derived library with coating antigens T1-BSA, T3-BSA and T5-BSA in our previous 
study 7. Sixteen VHHs panned with T3-BSA were selected for AP fusion, because these 
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VHHs showed better recognition to TBBPA than those from other coating antigens (data not 
shown). Based on the composition of CDRs, VHHs were distinguished into five groups. 
T3-4, T3-9, T3-12, T3-15, and T3-16 were chosen as a representative from each group 
(Figure S-2 in Supporting Information). AP is a highly attractive fusion partner due to both 
its high melting temperature (thermal stability) and the fact AP is a very stable colorimetric 
enzyme frequently utilized in ELISAs. The AP used in this study is 449 amino acids (~47 
KD) in length containing double mutations, D153G and D330N, the activity of which (kcat 
= 3200 s−1) is 40- to 50-fold higher than that of the wild-type bacterial enzyme (kcat = 65–
80 s−1) 35. The AP mutant-fusion proved to be easily produced in high yield in E. Coli., 
which served as a bifunctional immunoreagent combined recognition to most of the coating 
antigens while possessing high enzymatic activities (Figure 1). The expressed VHH-AP 
fusions with a 6×His tag were purified in a Ni-affinity chromatography protocol and one 
dominant band of around 62 KD (Figure S-3 in Supporting Information) was found upon 
SDS-PAGE analysis. The yield of each fusion protein by weight was around 30 mg from 1-
L bacterial culture media.
Binding Characteristics of VHH-AP Fusions
All the parental VHHs bound the coating antigens T3-BSA and T5-BSA, while T3-9 and 
T3-16 were also able to bind T1-BSA and T2-BSA (Figure 1A). However, the fusion 
proteins VHH-APs showed good binding to all the coating antigens except T4-BSA (Figure 
1B). The failure of both VHH and VHH-AP fusion to recognize hapten T4 indicated the 
importance of the bromine atom in the generation of antibody in alpacas. The VHH-AP 
fusions showed better binding with haptens T3 and T5 than with haptens T1 and T2 (Figure 
1B). The possible reason is that the immunizing hapten T5 is different from hapten T3 only 
having an additional 2-carbons in linker length, while different from haptens T1 and T2 in 
both linker length and spatial configuration (Figure S-1 in Supporting Information). It is 
noticeable that the TBBPA fragment-derived hapten T6 can be recognized by all VHH-AP 
fusions but not by parental VHHs (Figure 1). The paratope capacities of the VHH might be 
enlarged by fusion with the AP protein. It might be helpful in future studies to increase the 
paratope sizes and diversities. Because the bacterial AP usually exists as a symmetrical 
dimer 36, this could lead to unpredictable levels of complexity and aggregation 37. The 
dimerization and possible aggregation of the fusion protein likely contributed to the 
dramatic increase in affinity for the antigen 17, 38, 39. The binding affinities to TBBPA were 
evaluated for all VHH-AP fusions using one-step competitive ELISAs based on coating 
antigens T3-BSA and T5-BSA, both of which were well recognized by the VHH-AP 
fusions. The best assay sensitivity was obtained from T3-15-AP among all the VHH-AP 
fusions based on either T3-BSA or T5-BSA, indicating T3-15-AP had the highest binding 
affinity to TBBPA. Therefore, T3-15-AP was used for the remaining studies. The IC50 
values of one-step assays for TBBPA varied in a range of 0.4–1.7 ng mL−1 with coating 
antigens T1-, T2-, T3-, T5- and T6-BSA. The best sensitivity (IC50 = 0.4 ng mL−1) was 
obtained from the combination of T3-15-AP and the homologous coating antigen T5-BSA. 
In our previous study, T3-15 showed almost equivalent sensitivity to TBBPA in both 
coating antigens T5-BSA and T3-BSA, with IC50 values of 0.54 and 0.41 ng mL−1, 
respectively 7. Nevertheless, T3-15-AP showed a little higher sensitivity to TBBPA in T5-
BSA than in T3-BSA, with IC50 values of 0.39 and 0.69 ng mL−1, respectively (Figure S-4 
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in Supporting Information). The dimerization of AP fusion proteins possibly altered the 
binding ability of VHH, giving rise to the slight change for small molecule binding.
Optimization of the One-step ELISA
TBBPA, a lipophilic compound (Kow=4.5–5.3) 40, should be solubilized by organic solvents 
in immunoassay applications. Because the VHH was reported to be more tolerant to MeOH 
and DMSO than the pAb 8 and mAb 9, both of these solvents can be used as solubilizers to 
be miscible with water in the assay buffer. The optimal concentrations of coating antigen 
T5-BSA and T3-15-AP were determined by checkerboard titration. With the increase of 
MeOH in the range of 0–60%, A0 was typically enhanced from 1.02 to 1.46 A.U. and the 
IC50 values ranged from 0.4 to 1.1 ng mL−1. The best sensitivity was observed from the 
assay buffer containing 10% MeOH (IC50 = 0.4 ng mL−1) (Figure 2A). In the assay buffer 
with a range of 0–60% DMSO, the A0 changed between 1.41 and 1.53 A.U. and the IC50 
values ranged from 0.2 to 0.9 ng mL−1 (Figure 2B). The best sensitivity was obtained at the 
concentration of 5% DMSO, with an A0 of 1.1 A.U. and an IC50 of 0.2 ng mL−1. Similar 
calibration curves were observed in the assays performed in high concentrations of DMSO 
(20–60%), showing less sensitivity (IC50 = 0.8–0.9 ng mL−1) and more narrow linear ranges 
in comparison with those in low concentrations of DMSO (5–10%). Solvent tolerance is one 
of the important considerations for the application of one-step ELISA for the lipophilic 
compounds. No obvious shift was observed for the performance of the one-step ELISAs at 
pH 7.0–10.0, as the A0 and IC50 varied slightly in a range of 1.07–1.22 A.U. and 0.20–0.40 
ng mL−1, respectively (Figure 2C). Because the AP protein or the VHH might be denatured 
in the acidic or alkaline buffer, the fusion protein showed low binding affinity to TBBPA at 
pH ≤6.0 or ≥11.0 (Figure 2C).
Figure 3 is a typical calibration curve of T3-15-AP based ELISA for TBBPA under 
optimized conditions (5% DMSO, pH 7.4). The assay had a linear range of 0.03–0.94 ng 
mL−1 (IC20–IC80) and an IC50 of 0.2 ng mL−1. Compared to the T3-15 based ELISA (10% 
MeOH, pH 7.4, IC50 = 0.4 ng mL−1), the sensitivity was increased 2-fold in the T3-15-AP 
based ELISA. In spite of the slight improvement of sensitivity, the one-step assay protocol 
was simplified and less immunoreagents were required in this assay than in the VHH-based 
ELISA.
Cross-reactivity
The specificity of the T3-15-AP was evaluated by comparing the IC50 value of TBBPA with 
that of its structural analogs, including 2,2′,6,6′-tetrabromobisphenol A diallyl ether 
(TBBPA-bAE), tetrabromobisphenol A bis(2-hydroxyethyl) ether (TBBPA-bOHEE)s, 
hexabromocyclododecane (HBCD), PBDEs (BDE-47, BDE-99), hydroxylated BDE-47 
metabolites (5-OH-BDE-47 and 6-OH-BDE-47), 1,2-bis(pentabromodiphenyl) ethane 
(DBDPE) and bisphenol A (BPA), in one-step assays (Table 1). T3-15-AP showed similar 
specificity for TBBPA to the parental T3-15 7, having negligible cross-reactivity with the 
structural analogs (<0.1%). Multimerzation was reported to give rise to the effective 
affinity 17 on VHH-AP and the target, whereas, the specificity was likely determined in 
large part by the original antibody-analyte domain sites which appeared too rigid to be 
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altered dramatically 3, 37 and the spatial position of bromine atoms and phenolic hydroxyl 
groups in TBBPA.
VHH-AP Stability
The stability of VHH-AP and VHH was evaluated by simultaneously testing the effects of 
both high and ambient temperature on the binding activities of T3-15-AP and T3-15 to T5-
BSA and T3-BSA, respectively. T3-15 retained around 20% binding activity after heating at 
90 °C for 90 min 7, while T3-15-AP lost half of its activity after only 10 min and almost all 
the binding activity after 20 min (Figure S-5A in Supporting Information). It has been 
reported that mutant E. coli APs showed a lower melting temperature of 87 °C 30 and thus 
the VHH-AP fusion proteins were less thermostable than the single domain antibodies 37, 39. 
The thermal denaturation of AP and the irreversible refolding process may interfere with the 
thermal stability of the fusion protein. In contrast, the fusion protein T3-15-AP demonstrated 
much more stability at ambient temperature than T3-15 (Figure S-5B in Supporting 
Information). T3-15 lost all binding ability to coating antigens by the fourth day, while 
T3-15-AP retained full binding activity even after incubating for 70 days, which is an 
important consideration for on-site applications. Besides the full stability of the mutant AP 
protein 35, excellent resistance of dimerized proteins to digestion by trypsin, chymotrypsin 
and serum proteases might also contribute to the long-term storage of T3-15-AP at ambient 
temperature 37. Although protection reagents, such as inhibitors of growth bacteria (e.g. 
glycerol and NaN3), can retard the loss of VHH activities at some levels (Figure S-6 in 
Supporting Information), the dimerization of VHH-AP is a natural way to stabilize the 
VHH.
Matrix Effects
Dilution of sample extracts with assay buffer is one of the most common sample 
pretreatment methods to minimize matrix effects on ELISAs. The minimum dilution of 
sample to generate a standard curve similar to that generated in assay buffer was an 
indication of removal of matrix effects 41, 42. Because the VHH-AP based assay could be 
carried out in PBS containing up to 60% DMSO with an acceptable shift of IC50 values in a 
range of 0.2–0.9 ng mL−1 (Figure 2B), we presumed that the urine matrix effects could be 
minimized by directly diluting urine with DMSO, thus, improving the assay sensitivity in 
urine. The A0 value increased gradually from 0.62 A.U. in 10% of DMSO/urine (v/v) to 
0.91 A.U. in 60% of DMSO/urine and IC50 values ranged from 0.54 to 1.04 ng mL−1 
(Figure 4). At 60% of DMSO/urine, the responses of T3-15-AP to both T5-BSA and 
TBBPA were similar to those at 60% of DMSO/PBS (Figure 4). This suggests that urine 
matrix effects on the assay can be minimized by directly diluting with DMSO. A precipitate 
was produced with addition of DMSO. A possible reason is that a high concentration of 
DMSO not only solubilizes the TBBPA, but also denatures proteins or other materials 
sequestering TBBPA and precipitates salts and other materials giving rise to the matrix 
effects in urine. Another explanation might be that organic solvents activated a particle 
unfolding region of AP like myosin A 43 to produce more catalytic activity.
To match the assay requirement of urine samples diluted directly with DMSO, a new 
calibration curve of T3-15-AP based ELISA for TBBPA was generated in 60% of DMSO/
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PBS, showing an IC50 and an IC20 of 0.9 ng mL−1 and 0.23 ng mL−1, respectively. This 
calibration curve was used for sample analysis, with a minimum detection limit of 0.6 ng 
mL−1 in urine, which is more sensitive than other reports 44, 45.
Sample Analysis and Validation
Urine samples spiked with different concentrations of TBBPA were measured by both one-
step ELISA and HPLC-MS/MS methods. Using the simple dilution protocol with 60% of 
DMSO in urine, the recoveries of TBBPA from urine by the one-step assay were in a range 
of 96.7–109.9% and the detectable concentration of TBBPA was 1.0 ng mL−1 (Table 2). In 
the HPLC-MS/MS method, TBBPA below 20 ng mL−1 was not detectable but satisfactory 
recoveries in a range of 98.9–106.1% were obtained from urine with 20–100 ng mL−1 
TBBPA (Table 2). The results indicated that simple DMSO dilution is an acceptable 
pretreatment method for the detection of TBBPA in urine by the one-step ELISA which 
correlated well with HPLC-MS/MS.
Occurrence data on TBBPA in human urine are scarce and limited to a study on the 
toxicokinetics of TBBPA in humans 45, in which the concentrations of unchanged TBBPA 
were below the LOD of a LC-MS/MS method (0.3 nmol/L–4 μmol/L) in all urine samples 
collected after a single oral dose of 0.1 mg kg−1 TBBPA in individuals. Although the 
majority of the TBBPA in urine was excreted as the glucuronide or sulfate conjugate, the 
excretion might be hydrolyzed to the parent TBBPA or concentrated for the determination of 
the total TBBPA in one-step assay. Because of the high sensitivity, time-saving and easy 
operation, the one-step ELISA has potential for the evaluation of human exposure to 
TBBPA.
CONCLUSION
This study, in terms of the bifunctional VHH-AP fusion protein, presents an innovative 
competitive immunoassay for determining TBBPA in a single step. Bacterial AP, due to its 
high catalytic efficiency and stability, was selected to fuse with anti-TBBPA VHHs for 
direct colorimetric detection. The homodimeric nature of AP may enlarge the paratopes, 
enhance the flexibility and heighten the effective affinity of fused VHHs. The resistance of 
fusion proteins to organic solvents, heat and pH was quite different from parental VHHs, but 
superior to most polyclonal and monoclonal immunoreagents. The difference in the 
sensitivity and specificity between the VHH and the VHH-AP based assays were not 
evident, illustrating genetic attachment of the AP did not negatively impact the function of 
the VHH. However, the recognition of diverse coating antigens by VHH-AP was broader 
than the parent VHH possibly due to broader paratopes formed by the AP fusion. Increasing 
the percentage of DMSO in urine sample helped to minimize matrix effects on the T3-15-
AP based assay, allowing for the direct analysis of TBBPA in 60% of DMSO/urine with 
recoveries ranging from 96.7% to 109.9%. The sample pretreatment and assay protocol were 
simultaneously simplified. In all, this study demonstrated the utility of detecting small 
molecules using a genetically constructed VHH-AP immunoreagent, which reduced the 
number of steps needed in a conventional ELISA without altering sensitivity. In addition, 
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the VHH-AP fusion protein worked successfully in a urine matrix, demonstrating its 
potential for monitoring chemical exposure through rapid urine analysis.
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The responses of VHH and VHH-AP clones to different coating antigens by ELISA (A: 
VHH; B: VHH-AP).
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Effects of MeOH (A), DMSO (B) and pH (C) on the T3-15-AP based ELISA for TBBPA. 
ND: Not determined.
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Calibration curve of T3-15-AP based one-step ELISA for TBBPA. T5 was used as both the 
immunizing hapten and the coating hapten conjugated with thyroglobulin and BSA, 
respectively. Values are the mean ± standard deviations of three well replicates.
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Matrix effects of urine samples with different DMSO dilution on the one-step assay. The A0 
and IC50 of calibration curves prepared in DMSO/urine were compared with those prepared 
in DMSO/PBS.
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Table 1
Cross-Reactivity of VHH T3-15-AP with TBBPA Atructural Analogues.
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Table 2
Determination of TBBPA in urine samples by one-step ELISA and HPLC-MS/MS methods.
Spiked TBBPA (ng 
mL−1 urine)
One-step ELISA HPLC-MS/MS
Measured (ng mL−1) 
(Mean ± SD, n=3)
Average Recovery (%) Measured (ng mL−1) 
(Mean ± SD, n=3)
Average Recovery (%)
0 ND -- ND --
0.5 ND -- ND --
1 1.1 ± 0.1 109.9 ND --
5 4.8 ± 0.1 96.7 ND --
20 21.8 ± 0.8 108.8 19.8 ± 1.3 98.9
50 49.4 ± 2.8 98.7 50.2 ± 4.9 100.5
100 105.3 ± 5.8 105.3 106.1 ± 6.0 106.1
ND: Not detectable.
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